학술논문
Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
Document Type
Article
Author
Source
Subject
*NATALIZUMAB
*MONOCLONAL antibodies
*DRUG efficacy
*PHARMACODYNAMICS
*MULTIPLE sclerosis treatment
*PHYSIOLOGY
*
*
*
*
*
Language
ISSN
1352-4585
Abstract
The article examines the therapeutic effect of natalizumab on the microRNA (miRNA) expression pattern in multiple sclerosis patients. The study shows the effect of miRNA expression level after six months of the patient's therapy. The positive correlation between the miR-320 expression and the therapy time is noted.